Neurocognitive and observational markers: prediction of autism spectrum disorder from infancy to mid-childhood by Bedford, Rachael et al.
RESEARCH Open Access
Neurocognitive and observational markers:
prediction of autism spectrum disorder
from infancy to mid-childhood
Rachael Bedford1*†, Teodora Gliga2†, Elizabeth Shephard3, Mayada Elsabbagh4, Andrew Pickles1,
Tony Charman5 and Mark H. Johnson2
Abstract
Background: Prospective studies of infants at high familial risk for autism spectrum disorder (ASD) have identified a
number of putative early markers that are associated with ASD outcome at 3 years of age. However, some diagnostic
changes occur between toddlerhood and mid-childhood, which raises the question of whether infant markers remain
associated with diagnosis into mid-childhood.
Methods: First, we tested whether infant neurocognitive markers (7-month neural response to eye gaze shifts
and 14-month visual disengagement latencies) as well as an observational marker of emerging ASD behaviours (the
Autism Observation Scale for Infants; AOSI) predicted ASD outcome in high-risk (HR) 7-year-olds with and without an
ASD diagnosis (HR-ASD and HR-No ASD) and low risk (LR) controls. Second, we tested whether the neurocognitive
markers offer predictive power over and above the AOSI.
Results: Both neurocognitive markers distinguished children with an ASD diagnosis at 7 years of age from those in the
HR-No ASD and LR groups. Exploratory analysis suggested that neurocognitive markers may further differentiate stable
versus lost/late diagnosis across the 3 to 7 year period, which will need to be tested in larger samples. At both 7 and
14 months, combining the neurocognitive marker with the AOSI offered a significantly improved model fit over the
AOSI alone.
Conclusions: Infant neurocognitive markers relate to ASD in mid-childhood, improving predictive power over and above
an early observational marker. The findings have implications for understanding the neurodevelopmental mechanisms
that lead from risk to disorder and for identification of potential targets of pre-emptive intervention.
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Background
A key criticism of psychiatric diagnoses based on behav-
ioural criteria is that, unlike diagnoses elsewhere in
medicine, they lack a defined biological basis. Conse-
quently, some have argued for a more biologically based
approach within psychiatry based on phenotypes de-
scribed in terms of neurocognitive measures associated
to specific brain systems or pathways [1, 2]. In autism
spectrum disorder (ASD), a number of neurocognitive
phenotypes [3] have been identified during childhood
that are associated with the core ASD symptom domains
of social communication impairments, the presence of
restricted and repetitive patterns of behaviour and atyp-
ical sensory responses (Diagnostic and Statistical Man-
ual 5th edition (DSM-5) [4]). For early emerging
neurodevelopmental disorders such as ASD, there has
been an increasing emphasis on identifying earlier neu-
rocognitive phenotypes, that might be evident before the
onset of frank clinical symptoms, and which are referred
to as ‘antecedents’ [5]. In the past decade, the use of a
prospective familial high-risk design, with a recurrence
rate close to 20% [6, 7], has enabled the discovery of a
variety of antecedents of later ASD symptoms from the
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first few months of life. Indices of infant behavioural and
neural atypicalities, both measured through observa-
tional scales and specific infant neurocognitive markers,
as well as various neuroimaging methods, have been
shown to associate with a later ASD diagnosis in
toddlerhood (for reviews, see [8–10]). Observational
scales and neurocognitive measures use different ap-
proaches to measuring psychopathology. The former
aims to measure the extent of atypicality by counting the
occurrence of a broad spectrum of behaviours; for ex-
ample, the Autism Observation Scale for Infants (AOSI
[11]) assesses behaviours such as the anticipation of so-
cial interaction, imitation and motor skills. Total scores
measured when infants at risk for ASD are 1 year old
predict later ASD symptoms and diagnostic outcome
[12, 13]. In contrast, neurocognitive measures are de-
signed to index the functioning of particular cognitive or
neural systems. The British Study for Infant Siblings
(BASIS) has published on several such neurocognitive
markers [10]. Two of those that showed an association
with 3-year-old ASD diagnosis are reduced differenti-
ation in the neural response to eye gaze shifts towards
versus away from the infant at 7 months of age, mea-
sured by the amplitude of the P400 event-related poten-
tial (ERP) component [14] and prolonged attention
disengagement latency at 14 months of age, measured in
a visual orienting task [13, 15, 16].
The extent to which such antecedents are predictive
markers for diagnosis beyond early childhood is, as yet,
unexplored, with most studies reporting prediction of 2
and 3 year diagnosis. As with other behaviourally de-
fined disorders [17], it is known that there is change in
individual trajectories of ASD manifestation over time,
particularly in early childhood [18–21]. In different chil-
dren, symptoms can ease or worsen to the extent that
children move above and below specific diagnostic
thresholds [22–24]. The only two high-risk sibling stud-
ies that have reported to date on stability of diagnosis to
mid-childhood [25, 26] both found overall good agree-
ment in clinical best-estimate diagnosis of ASD between
3 years and mid-childhood. However, in both studies,
the diagnosis was not entirely stable. Brian et al. [25]
found one individual out of 18 classified as ASD at
3 years of age no longer met criteria in middle childhood
(9 years), and 6 high-risk children out of 49 who were
not considered to meet criteria for ASD at 3 years went
on to be later diagnosed. A similar pattern emerged
in our mid-childhood follow-up of the present sample
at age 7 years [26], where 3 out of 13 children con-
sidered to meet ASD diagnostic criteria at 3 years did
not at the mid-childhood assessment, and 5 out of 29
children who were not considered to meet ASD
criteria at 3 years did so at 7 years. The latter pattern
is consistent with the notion, included in DSM-5, that
in some children with ASD, symptoms might not become
apparent until ‘demands exceed capacity’ [4]. This is con-
sistent with our clinical experience that for some chil-
dren—often those with high general ability, good language
and relatively intact non-verbal communication skills—it
is only when they enter preschool, where they are faced
with increased expectations of behaviour, in particular
their responses to peers and unfamiliar adults, that par-
ents, carers and other professionals become concerned
about possible atypical development.
Given the diagnostic change from early childhood, the
question arises as to whether markers remain predictive
of ASD diagnosis into mid-childhood. In the current
study, we first aim to test whether two previously re-
ported infant neurocognitive markers, indexing eye-gaze
processing [14] and attention control [15] and one ob-
servational scale of early emerging behavioural atypical-
ities (the AOSI) [12], shown to be associated with ASD
outcome at 3 years of age, also distinguish high risk
(HR) children with and without a diagnosis of ASD at
age 7 years. To our knowledge, this is the first report of
an association between infant neurocognitive markers
and mid-childhood ASD diagnosis. Our second aim is to
establish how the markers work in combination, by test-
ing whether inclusion of the neurocognitive marker (i.e.
P400 in response to gaze shifts or disengagement) in the
same model as the AOSI (measured concurrently with
the neurocognitive marker, i.e. 7 or 14 months) im-
proved prediction of ASD outcome over the AOSI alone.
Methods
Participants
As part of the British Autism Study of Infant Siblings
(BASIS: http://basisnetwork.org/), one hundred and four
infants (54 high risk, 21 male; 50 low risk, 21 male) took
part in a battery of assessments at 7 and 14 months and
2, 3 and 7 years. At enrolment, each high risk (HR) in-
fant (n = 54) had an older sibling (in 4 cases, a half-
sibling) with a community clinical ASD diagnosis, con-
firmed using information from the Development and
Well-Being Assessment (DAWBA [27]) and the Social
Communication Questionnaire (SCQ [28]) by expert cli-
nicians on our team (TC, PB).1 Low risk (LR) controls
(n = 50) were full-term infants (with one exception)
recruited from a volunteer database at the Birkbeck
Centre for Brain and Cognitive Development. For older
siblings of LR infants, the SCQ was used to confirm
absence of ASD, with no child scoring above instrument
cut-off (≥ 15; n = 1 missing data).
Of 53 HR and 48 LR children retained at the 3-year
assessment, 44 HR (83%) and 37 LR (77%) agreed to take
part in the follow-up study at 6–8 years. Of these, two
HR children did not complete a research visit (parents
completed questionnaires only). As we did not see these
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children, we were unable to assign them to an ASD out-
come group and consequently excluded them from the
current analyses, leaving a final sample of 42 HR siblings
(15 boys, 27 girls) and 37 LR controls (15 boys, 22 girls).
The retained sample did not differ from the non-
retained sample in 3 year levels of ASD on the Autism
Diagnostic Observation Schedule—Generic (ADOS-G [29]),
Social Responsiveness Scale—Second Edition (SRS-2 [30])
or SCQ, developmental level on the Mullen Scales of
Early Learning (MSEL [31]), adaptive behaviour assessed
with the Vineland Adaptive Behavior Scales—Second
Edition (VABS-II [32]), or family income (all p > 0.4).
The HR and LR groups did not differ in age (HR mean
(SD) 90.6 (6.3) months; LR mean (SD) 89.3 (4.9) months;
t(74) = − 1.00, p = 0.31) or sex (HR % male 35.7; LR %
male 40.5; Ӽ2 (1) = .20, p = 0.66) at the follow-up. Ethical
approval was obtained from the NHS National Research
Ethics Service (NHS RES London REC 08/H0718/76;
14/LO/0170). Parents provided written informed
consent. At the mid-childhood visit, children provided
written informed assent wherever possible given de-
velopmental level.
Procedure
The association between infant neurocognitive markers
(neural gaze processing and disengagement latencies) as
well as the AOSI scores and 3 year ASD outcomes has
been previously reported (see [12, 14, 15] for full descrip-
tion of the methods). See Additional file 1 for details of
our other previously published antecedent biomarkers.
Gaze processing task: P400 difference score (see [14])
In this task, infants saw images of four female faces with
gaze directed either towards or away from the infant.
Each trial block began with a static colourful fixation
stimulus followed by three to six face stimuli (same
identity) alternating between direct gaze and averted
gaze. This gave the impression of gaze shifts away and
towards the infant. Faces were aligned with the centre of
the screen with the eyes appearing at the same location
as the fixation stimuli, to ensure that infants were fixat-
ing the eye region. The faces subtended 21 × 14 degrees
of visual angle. Fixation stimuli, preceding the onset of
the face and noise stimuli, subtended approximately
1.6 × 1.6 degrees and were presented for a variable dur-
ation of 800 to 1200 ms. Each trial lasted for 1000 ms.
Infants wore a 128 channel Hydrocel Sensor Net on their
head and were seated on the parent’s lap in front of the
stimulus screen. When the infant was attending to the
screen, trials were presented continuously for as long as the
infant remained attentive, with brain electrical activity mea-
sured simultaneously using the vertex as a reference (Cz in
the conventional 10/20 system). EGI NetAmps 200 was
used (gain = 1000). Data were digitised with a sampling rate
of 500 Hz and band-pass filtered between 0.1 and 100 Hz.
Segmented data were processed using standard procedures
including interpolation of missing channels, re-referencing
to the average reference and baseline correction. Subse-
quent to artefact rejection, ERP components were ascer-
tained based on visual inspection of grand averages. Three
task-sensitive components (P100 120–199 ms, N290 200–
319 ms and P400 320–520 ms) were ascertained over the
occipito-temporal region, and their characteristic amplitude
and latency were computed for each infant. Elsabbagh
and colleagues [15] reported on P400 differences in re-
lationship to 3-year-old diagnosis, with infants who
went on to develop ASD showing less discrimination of
away versus towards gaze shifts. We therefore focus on
the same component. There were no significant out-
come group differences (LR, HR-No ASD, HR-ASD) in
the number of trials included in the analysis of the
P400, F(2, 69) = 1.84, p = 0.17.
Attention Disengagement (see [15])
Infants were presented with the stimuli on a 46″ LCD
monitor, while seated on their parent’s lap at 60cm dis-
tance. Looking behaviour was recorded with a video
camera, and trial presentation was controlled by the ex-
perimenter. Each trial began with a central stimulus
(subtending 13.8° × 18.0°) followed by a peripheral target
green balloon (subtending 6.3° × 6.3°) which appeared
randomly on the left or right. The target remained on
the screen until either (1) the infant looked at it or (2)
the maximum time of 2.5 s passed. An animal reward
stimulus (elephant, lion, seal etc.) then appeared in the
place of the green balloon. Up to 70 trials were pre-
sented depending on infants’ attentiveness. There were
two trial types in this study: baseline and overlap. In the
baseline condition, the central stimulus disappeared at
the same time as the peripheral target appeared, whereas
in the overlap condition, the central stimulus remained
present while the target stimulus appeared in the periph-
ery. Elsabbagh and colleagues [15] reported on disen-
gagement (the saccadic reaction time difference between
overlap and baseline trials) in relation to 3-year-old diag-
nosis, with infants who later developed ASD showing
the longest disengagement latencies. We therefore focus
on the same measure in this paper. The number of valid
trials did not differ by outcome group: F(2, 72) = 1.02,
p = 0.37 (see Table 1).
The Autism Observation Scale for Infants (AOSI [11,
12]) is a semi-structured observational assessment of
ASD behavioural markers in infancy collected at 7 and
14 months. In the current study, a 19-item version of
the AOSI was used (see [33]) which gives a total score
(sum of all codes; max score 44), with higher scores
indexing greater atypicality. The majority of assessments
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were double coded with excellent reliability (n = 85,
intraclass correlation coefficient = 0.95).
ASD outcome at 7 years of age
To ascertain ASD diagnostic outcome according to
DSM-5, four experienced researchers (ES, BM, GP, TC)
reviewed information on ASD symptomatology (ADOS-
2, Autism Diagnostic Interview—Revised, ADI-R [34] and
SCQ; for HR participants only) and adaptive functioning
(VABS-II) and IQ (Wechsler Abbreviated Scale of Intelli-
gence—Second Edition, WASI-II [35]) for each HR and
LR child. Clinicians were not involved in the infant visits
when the experimental tasks were administered. Diagno-
sis at age 7 years included review of all information pre-
viously obtained, and there was overlap in the personnel
involved in the diagnostic decision-making (GP, TC).
However, the age 7 diagnostic decisions were not dir-
ectly yoked to the diagnostic decisions previously taken
at the 3-year visit but an independent decision was made
as to whether, based on all the clinical information col-
lected at the 2-, 3- and 7-year assessments, the child
currently met DSM-5 criteria for ASD. Fifteen HR chil-
dren (7 boys, 8 girls) met DSM-5 (APA, 2013) criteria
for ASD at age 7, and the remaining 27 HR children (8
boys, 19 girls) did not. Of 13 HR siblings with an ASD
diagnosis at 3 years who were also seen at 7 years, 10
retained their ASD diagnosis (76.9%, ‘stable diagnosis’)
and 3 did not (23.1%, ‘lost diagnosis’). Of the 29 HR who
were not given an ASD diagnosis at 3 years also seen at
7 years, 24 did not meet diagnostic criteria for ASD
(82.8%) at 7 years but 5 did meet ASD criteria (17.2%,
‘late diagnosed’). The 15 HR children meeting DSM-5
criteria for ASD at age 7, including the 5 ‘later diag-
nosed’ children, formed the HR-ASD group. Of the 27
HR children who did not meet ASD criteria at age 7, the
3 ‘lost diagnosis’ children were excluded from further
analysis (given they met ICD-10 criteria [36] for ASD earl-
ier in development), leaving 24 HR children in the HR-No
ASD group (see Additional file 1 for more information on
the groups split by diagnostic change). None of the 37 LR
children met DSM-5 criteria for ASD, and none had a
community clinical ASD diagnosis at 3 years nor at 7 years.
Group characteristics at age 7 are presented in Table 2.
Statistical analysis
Analyses were run using SPSS [37] and Stata [38].
First, to assess the association between neurocognitive
markers and ASD outcome in mid-childhood, separate
Table 1 Neurocognitive markers and Autism Observation Scale for Infants at 7 and 14 months
Low risk High-risk No ASD High-risk ASD
Visit 1 P400
7 months Valid trial no. 57.02 (32.61) 69.61 (32.15) 50.18 (30.24)
Mean (SD) 3.11 (4.02) 1.63 (3.37) − 2.02 (6.78)
N (girls) 33 (20) 23 (18) 14 (8)
AOSI
Mean (SD) 6.70 (3.67) 9.25 (5.14) 8.80 (7.39)
N (girls) 37 (22) 24 (19) 15 (8)
Mullen ELC
Mean (SD) 102.86 (10.76) 95.83 (9.88) 95.40 (18.39)
N (girls) 37 (22) 24 (19) 15 (8)
Age (months) 7.30 (1.18) 7.46 (1.22) 7.47 (1.36)
Visit 2 Disengagement
14 months Valid trial no. 27.03 (6.64) 26.86 (7.78) 24.20 (4.86)
Mean (SD) 144.19 (102.88) 125.04 (135.13) 237.05 (122.73)
N (girls) 36 (22) 22 (17) 15 (8)
AOSI
Mean (SD) 3.31 (3.57) 3.30 (3.20) 7.53 (5.45)
N (girls) 37 (22) 23 (18) 15 (8)
Mullen ELC
Mean (SD) 108.46 (15.28) 104.48 (11.74) 93.33 (16.29)
N (girls) 35 (22) 23 (18) 15 (8)
Age (months) 13.72 (1.26) 13.74 (1.45) 13.80 (1.94)
AOSI Autism Observation Scale for Infants, ELC Early Learning Composite
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multinomial logistic regressions were run, with 7-
month AOSI and P400, and 14-month AOSI and dis-
engagement latency, respectively, as predictors. For
ASD outcome, the reference category was the HR-
ASD group, with pairwise comparisons presented for
LR versus HR-ASD, and HR-No ASD versus HR-ASD.
In follow-up models, sex was entered as a factor but it
did not impact the contribution infant markers made
to predicting outcome (see Additional file 1). Next, to
enable a direct comparison of the neurocognitive
markers with observational markers of early ASD be-
haviours, the AOSI total score at 7 and 14 months
and neurocognitive markers (P400 and disengage-
ment latency, respectively) were included as predic-
tors in the same logistic regression model, one for
7 month predictors and one for 14 month predic-
tors. The chi-squared model fit for the model with
each neurocognitive marker together with AOSI was
then compared to that with AOSI or the neurocog-
nitive marker alone.
Results
Association between infant markers and ASD outcome
When measured at 7 months, the AOSI total score was
not a significant predictor of ASD outcome χ2(2) = 4.40,
p = 0.11. At 14 months, however, AOSI score did signifi-
cantly predict ASD outcome χ2(2) = 10.64, p = 0.005, with
the HR-ASD group showing higher AOSI scores than LR
controls (B = − 0.215, SE = 0.080, odds ratio = 0.81,
p = 0.007) and HR-No ASD (B = − 0.215, SE = 0.089, odds
ratio = 0.81, p = 0.016).
Seven-month P400 amplitude difference score was a
significant overall predictor of the ASD outcome
(χ2(2) = 12.15, p = 0.002; see Fig. 1a), with the HR-ASD
group differentiating less between the away and towards
gaze shifts than LR controls did (B = 0.288, SE = 0.10,
odds ratio = 1.33, p = 0.005). HR-ASD and HR-No ASD
groups differed only marginally (B = 0.187, SE = 0.099,
odds ratio = 1.21, p = 0.059). Results were substantively
similar when one outlier was trimmed (see Additional
file 1). Disengagement latency at 14 months also
Table 2 Descriptive statistics from the 7-year visit RB
Low risk High-risk No ASD High-risk ASD Group differences
Age (months)
Mean (SD) 89.34 (4.81) 91.42 (6.28) 89.13 (6.53) n/s
N (girls) 35* (21) 24 (19) 15 (8)
ADI-social
Mean (SD) Not completed 4.04 (5.48) 13.14 (4.69) t(36) = − 5.20, p < 0.001
N (girls) 24 (19) 14 (8)
ADI communication
Mean (SD) Not completed 4.25 (4.67) 10.43 (4.59) t(36) = − 3.96, p < 0.001
N (girls) 24 (19) 14 (8)
ADI RRB
Mean (SD) Not completed 0.58 (1.41) 3.57 (1.74) t(36) = − 5.77, p < 0.001
N (girls) 24 (19) 14 (8)
ADOS CSS total
Mean (SD) 1.70 (1.19) 2.46 (1.41) 6.20 (2.78) F(2, 69) = 37.35, p < 0.001, η2 = 0.520
N (girls) 33 (19) 24 (19) 15 (8)
ADOS CSS SA
Mean (SD) 2.18 (1.70) 2.96 (1.60) 6.60 (2.59) F(2, 69) = 29.11, p < 0.001, η2 = 0.458
N (girls) 33 (19) 24 (19) 15 (8)
ADOS CSS RRB
Mean (SD) 1.12 (0.70) 3.04 (2.84) 6.13 (2.70) F(2, 69) = 29.80, p < 0.001, η2 = 0.463
N (girls) 33 (19) 24 (19) 15 (8)
WASI FSIQ
Mean (SD) 117.06 (11.61) 107.96 (12.76) 109.79 (21.36) F(2, 70) = 3.25, p = 0.05, η2 = 0.085
N (girls) 35 (21) 24 (19) 14 (8)
*Two LR children completed questionnaires only; an exact age at visit was not available for these children
ADI Autism Diagnostic Interview—Revised, RRB Repetitive and restrictive behaviour, ADOS Autism Diagnostic Observation Schedule, CSS Calibrated severity score,
SA Social affect, WASI-II Wechsler Abbreviated Scale of Intelligence—II Full-Scale IQ, n/s non-significant
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predicted overall ASD outcome (χ2(2) = 9.55, p = 0.008; see
Fig. 1b), with the HR-ASD group having significantly longer
latencies than both other groups (LR: B = − 0.008, SE = 0.003,
odds ratio = 0.99, p = 0.015; HR-No ASD: B = − 0.009,
SE = 0.004, odds ratio = 0.99, p = 0.008) (Fig. 2).
Prediction of neurocognitive and observational markers
combined
In the combined model at 7 months, the omnibus
test was significant χ2(4) = 14.97, p = 0.005, with
P400 (χ2(2) = 10.54, p = 0.005 but not AOSI
(χ2(2) = 2.82, p = 0.24) predicting overall ASD out-
come groups. The P400 discriminated the HR-ASD
group from LR controls (B = 0.271, SE = 0.10, odds
ratio = 1.31, p = 0.008) but only marginally from HR-
No ASD (B = 0.191, SE = 0.10, odds ratio = 1.21,
p = 0.057). The model containing both P400 and 7-
month AOSI as predictors had a significantly better
chi-squared model fit compared to the AOSI alone
χ2(2) = 10.54, p = 0.005 but was not significantly bet-
ter than P400 score alone χ2(2) = 2.82, p = 0.24.
The omnibus test for the combined model at 14 months
was significant χ2(4) = 18.31, p = 0.001. Both the AOSI
(χ2(2) = 8.76, p = 0.013) and disengagement latency signifi-
cantly predicted ASD outcome (χ2(2) = 6.56, p = 0.038),
discriminating HR-ASD from both other outcome groups
(AOSI: LR: B = − 0.206, SE = 0.086, odds ratio = 0.81,
p = 0.017; HR-No ASD: B = −0.244, SE = 0.11, odds
ratio = 0.78, p = 0.021; Disengagement: LR: B = − 0.007,
SE = 0.004, odds ratio = 0.99, p = 0.04; HR-No ASD: B = −
0.009, SE = 0.004, odds ratio = 0.99, p = 0.023). The com-
bined disengagement and AOSI at 14 months improved
chi-squared model fit by χ2(2) = 6.56, p = 0.04 compared to
AOSI alone and by χ2(2) = 8.76, p = 0.01 compared to dis-
engagement alone.
Fig. 1 a P400 difference score at 7 months by 7-year-old ASD outcome. b Disengagement latency at 14 months by 7-year-old ASD outcome
Fig. 2 a AOSI Total Score at 7 months by 7-year-old ASD outcome. b AOSI Total Score at 14 months by 7-year-old ASD outcome
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Analysis taking into account the changes in diagnosis
between 3 and 7 years of age
Due to the very low sample sizes of the ‘late diagnosis’
(n = 5) and ‘lost diagnosis’ (n = 3) groups, who had un-
stable patterns of meeting ASD diagnostic criteria across
the 3- and 7-year assessments, it was not possible to sta-
tistically assess how neurocognitive and observational
measures mapped on various trajectories in clinical
manifestation. However, since neither the infant neuro-
cognitive markers, P400 and disengagement, nor the
AOSI have previously been examined in relation to such
subgroups, we illustrate the distribution of scores on
these measures in Fig. 3a and b and Fig. 4a and b. These
distributions are suggestive of differential underlying
mechanisms driving different profiles of ASD manifest-
ation over early childhood.
Discussion
This is the first study to demonstrate that infant ante-
cedent markers, eye-gaze processing at 7 months and at-
tention disengagement at 14 months, are associated with
ASD diagnostic outcome in mid-childhood. Further, we
show that at 7 months, P400 provides a better mapping
onto mid-childhood ASD diagnosis than a concurrent
observational measure of behavioural atypicality alone.
Combining P400 with behavioural symptoms from the
AOSI significantly improved the model fit compared to
the AOSI alone, but the joint model did not improve
prediction significantly compared to P400 alone. At
14 months, both neurocognitive and observational mea-
sures predicted ASD diagnosis in mid-childhood. A
model incorporating both disengagement and 14-month
AOSI was significantly better than having either AOSI
alone or disengagement alone. Thus, at both infant ages,
neurocognitive markers account for additional variation
in the expression of later ASD outcome. However, at
14 months, the enhanced prediction from combining
markers also emphasises that assessing a variety of mea-
sures of risk—including in this case both observational
measures of early emerging ASD behaviours and experi-
mental measures of neurocognitive function—in early
infancy might remain the optimal approach to early
screening. Multiplicative and additive models of ASD
risk have been suggested [39], and certain infant neuro-
cognitive markers have already been shown to predict
ASD outcome in additive manner [40].
Although our results indicate that measuring specific
neurocognitive systems may have as good, if not better,
predictive power than comprehensive measures of be-
havioural atypicality, especially at an age when under-
lying ASD pathology has not yet exerted broader
downstream effects on cognitive development, we are
not yet able to advocate the use of ERPs or other neuro-
cognitive phenotypes in ASD screening or diagnosis.
Replication of both the infant neurocognitive markers
and their association with 7-year outcome will be crit-
ical, as well as further validation steps such as test-retest
reliability. Nevertheless, given the apparent added bene-
fit of including the neurocognitive markers in addition
to the AOSI, the next translational step may be to use
these neurocognitive markers in triaging at-risk cases,
initially identified on the basis of a screening tool or
family risk.
Prediction from infant markers to mid-childhood out-
come mirrored prediction of 3-year-old outcome (see
Additional file 1). At both 3 and 7 years, the P400 differ-
entiated HR-ASD and LR groups, but only marginally the
HR-ASD and HR-No ASD groups. Similarly, for both the
3- and 7-year-old ASD outcome, attention disengagement
differentiated HR-ASD from the other two groups.
Fig. 3 a P400 difference score at 7 months by stability of ASD outcome between 3 and 7 years. b Disengagement latency at 14 months by stability of
ASD outcome between 3 and 7 years
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Similarity in prediction was found despite diagnostic
change occurring between 3 and 7 years of age—with
some of the children with a ‘late diagnosis’ joining the
HR-ASD group (n = 5) and others, the ‘lost diagnosis’
(n = 3) leaving the group, at 7 years of age [26]. This may
suggest that these two groups have similar profiles; per-
haps children who meet criteria at just one time point
have less severe symptoms and are closer to the diagnostic
threshold. Although sample sizes prevented us from asses-
sing group differences statistically, the descriptive statistics
do not support the late and lost diagnosis groups having
substantially less severe scores on the ADOS or the ADI
compared to those with stable ASD (see Additional file 1:
Table S1). Further, it is worth noting that the neurocogni-
tive markers described in this paper showed differential
group patterns across the ‘late’ and ‘lost’ diagnostic groups;
while P400 effect showed lower (i.e. more atypical) values
in both the late and stable ASD groups (i.e. those with a
diagnosis at 7 years of age), poor disengagement mainly
characterised the stable ASD group.
There is mounting evidence from twin studies that
symptom stability over time indicates a high degree of
genetic influence [41], possibly involving genes associated
with neural plasticity [42]. Some markers might thus re-
flect the brain’s ability to adapt to early disturbance, delay-
ing the onset of overt symptoms to later in childhood,
while others might index highly penetrant traits leading to
a stable expression of ASD symptoms throughout child-
hood. In terms of translational opportunities, under-
standing more about the underlying neurocognitive
developmental processes that lead to different trajectories
of phenotypic expression may also provide unique win-
dows of opportunity for early detection and screening [43]
or targeting pre-emptive interventions according to differ-
ent patterns of early neurocognitive and behavioural man-
ifestations [44, 45]. Larger samples will be required to test
whether there are different patterns of early antecedent
marker prediction of longitudinal trajectories of ASD
symptoms, whether considered in dimensional or cate-
gorical (diagnostic) terms, and this is an important goal of
future work.
Limitations
Although 7 year diagnosis was not directly yoked to the
diagnostic view reached at 3 years (as evident from the
instability we report, see [26] for discussion), one signifi-
cant limitation of the current study is the lack of inde-
pendence between the 3 year and 7 year diagnostic
judgements in that some of the clinical researchers were
involved in both. It is also worth noting that the AOSI is
the only measure of early ASD behaviours available from
this cohort at the same time-point as the neurocognitive
markers, whereas the neurocognitive markers reported
in the main text of the paper are those ‘pre-selected’ as
significantly related to 3-year ASD outcome in this sample.
Replication in independent samples using a pre-defined
analysis plan is thus necessary, and we are currently
attempting to replicate the current findings in a separate
cohort of children. Finally, as with all research utilising the
familial high-risk sibling design, the generalisability to the
wider population of children with ASD who are not from
multiplex families cannot be assumed [46].
Conclusion
While the focus of most of the work on predictive infant
neurocognitive markers of ASD conducted to date has
been on predicting diagnostic outcome at 2 or 3 years of
age [10], the current study emphasises the value of
continued follow-up of these cohorts through childhood.
While future replication in independent samples is
required, our results demonstrate the potential of ante-
cedent markers indexing neurocognitive systems to
Fig. 4 a AOSI total score at 7 months by stability of ASD outcome between 3 and 7 years. b AOSI total score at 14 months by stability of ASD
outcome between 3 and 7 years
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improve early prediction of mid-childhood diagnosis of
ASD. Further, such studies may help elucidate the
neurodevelopmental mechanisms that underlie different
developmental trajectories, as well as the environmental
influences that affect developmental change and out-
come in all children. In future, prospective longitudinal
studies may uncover distinct neurodevelopmental me-
chanisms that lead from risk to disorder and highlight
translational opportunities for screening and pre-
emptive intervention.
Endnotes
15 DAWBA and 5 SCQ missing
Additional file
Additional file 1: Supplementary materials. (DOCX 39 kb)
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